Gilead Buys Oxford Spin-out MiroBio

Gilead Sciences has agreed to acquire MiroBio, a privately held UK biotech focused on treating inflammatory diseases, for about $405 million in cash.

Spun out of Oxford University in 2019, MiroBio has a proprietary discovery platform and portfolio of immune inhibitory receptor agonists. The I-ReSToRE platform – Receptor Selection and Targeting to Reinstate immune Equilibrium – has potential to be used to develop best-in-class agonist antibodies targeting immune inhibitory receptors, a novel approach for the treatment of inflammatory diseases.

Chairman of MiroBio, Eliot Charles, commented: “MiroBio has a deep understanding of checkpoint receptor signaling and a proprietary approach to select and generate superior agonist antibodies. Combining this with Gilead’s drug development and therapeutic area expertise will allow us to fully explore the potential of checkpoint agonist antibodies for patients with autoimmune disease.”

MiroBio’s lead investigational antibody MB272 has entered Phase 1 clinical trials, and another – a PD-1 agonist – is reported to be in preclinical testing. Gilead anticipates advancing additional agonists from the I-ReSToRE platform over the next several years.

Author: Elaine Buridge, Freelance Journalist

© lichtmeister/shutterstock
© lichtmeister/shutterstock

Company

Logo:

Gilead Sciences, Inc.


Foster City, CA
US

Company contact







Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.